Reducing Protein Aggregation in a Bispecific Antibody Formulation
Protein aggregation is an important consideration in bispecific antibody formulation development, as apparent high-molecular-weight species may affect product quality and complicate formulation selection.
In this case, a bispecific antibody exhibited a relatively high level of protein aggregates when formulated in conventional buffer systems. A formulation investigation was conducted to determine the underlying cause of the observed high-molecular-weight species and identify formulation conditions with improved SEC performance.
The study demonstrated that the observed high-molecular-weight species were reversible aggregates. By identifying and excluding a formulation component associated with aggregate formation, a formulation with improved SEC performance was successfully established.
Development Challenge
The bispecific antibody showed a relatively high aggregate level in conventional buffer systems.
The key challenges included:
- High apparent aggregate content in the initial formulation
- Unclear origin of the high-molecular-weight species
- Need to distinguish reversible aggregation from other potential product-related species
- Need to identify formulation conditions with improved SEC performance
A systematic formulation investigation was therefore required to understand the aggregation behavior and guide formulation selection.
Formulation Development Strategy
A targeted investigation combining buffer system screening and SEC method optimization was conducted to characterize the observed high-molecular-weight species and identify suitable formulation conditions.
Buffer System Screening
Different buffer systems were evaluated to investigate the influence of formulation conditions on the observed aggregate level.
Key Focus:
Buffer Screening
Protein Stability
Aggregation Behavior
SEC Method Optimization
The SEC analytical method was optimized to support a more reliable assessment of the high-molecular-weight species and their aggregation behavior.
Key Focus:
SEC Method Optimization
Aggregate Characterization
Analytical Evaluation
Reversible Aggregate Investigation
The combined formulation and analytical studies demonstrated that the observed high-molecular-weight species were reversible aggregates.
Key Focus:
Reversible Aggregation
High-Molecular-Weight Species
Root Cause Investigation
Formulation Screening
Based on the investigation results, the formulation screening strategy was adjusted to exclude the specific component associated with the undesirable aggregation behavior.
Key Focus:
Component Selection
Formulation Screening
SEC Performance
Results
The investigation established that the elevated high-molecular-weight species observed in the initial formulation were reversible aggregates.
The formulation development strategy was subsequently adjusted to avoid the specific component associated with the aggregation behavior. The resulting formulation demonstrated improved SEC performance and was selected for further development.
Improved SEC Performance
Exclusion of the identified formulation component during formulation screening resulted in a formulation with a more favorable SEC profile and reduced aggregation-related concerns.
Key Outcomes
- High-molecular-weight species were identified as reversible aggregates
- Buffer systems were evaluated to investigate aggregation behavior
- SEC methodology was optimized to support the investigation
- The formulation component associated with aggregation was identified and excluded
- Improved SEC performance was achieved
- The program successfully progressed through IND submission and into clinical development
Project Outcome
The study provided a clear understanding of the aggregation behavior of the bispecific antibody and demonstrated the importance of evaluating formulation components when addressing apparent high-molecular-weight species.
By combining buffer system screening with SEC method optimization, the reversible nature of the aggregates was identified and an appropriate formulation strategy was established. The selected formulation demonstrated improved SEC performance, and the project subsequently successfully progressed through IND submission and into clinical development.
Related Services
